KRAS+ NSCLC

Being able to treat patients with non–small cell lung cancer (NSCLC) and a KRAS mutation with sotorasib has been exciting, and now there’s another drug available with the approval of adagrasib at the end of 2022, explained Lucio Gordan, MD, of Florida Cancer Specialists & Research Institute.

Alexander Spira, MD, PhD, a medical oncologist and director of VCS Research Institute & Phase I Trial Program, Virginia Cancer Specialists, discusses unmet needs and treatment with KRAS-mutated non–small cell lung cancer (NSCLC).

Joshua Sabari, MD, a thoracic medical oncologist, Perlmutter Cancer Center, NYU Langone Health, discusses actionable mutations in advanced non–small cell lung cancer (NSCLC).